The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
Official Title: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient Population
Study ID: NCT04972097
Brief Summary: Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Detailed Description:
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
University of California Irvine, Orange, California, United States
University of Colorado, Aurora, Colorado, United States
University of Florida Health, Gainesville, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Rush University Medical Center, Chicago, Illinois, United States
Northshore University Healthsystem, Evanston, Illinois, United States
Duly Health and Care, Lisle, Illinois, United States
VA Ann Arbor Health Care, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
NYU Langone Health, New York, New York, United States
Northwell Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Weill Cornell Medicine, New York, New York, United States
Duke University, Durham, North Carolina, United States
University of Cincinnati, Cincinnati, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Name: Jonathan Coleman, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Arvin George, MD
Affiliation: University of Michigan
Role: PRINCIPAL_INVESTIGATOR